Cost-Effectiveness Analysis of a Silver-Coated Endotracheal Tube to Reduce the Incidence of Ventilator-Associated Pneumonia

@article{Shorr2009CostEffectivenessAO,
  title={Cost-Effectiveness Analysis of a Silver-Coated Endotracheal Tube to Reduce the Incidence of Ventilator-Associated Pneumonia},
  author={Andrew F. Shorr and Marya D. Zilberberg and Marin H. Kollef},
  journal={Infection Control \&\#x0026; Hospital Epidemiology},
  year={2009},
  volume={30},
  pages={759 - 763}
}
Objective. To conduct a cost-effectiveness analysis of the economic outcomes of ventilator-associated pneumonia (VAP) prevention associated with silver-coated endotracheal tubes versus uncoated endotracheal tubes. Design. We used a simple decision model based on a hypothetical 1,000-patient cohort intubated with silver-coated or uncoated endotracheal tubes. The primary end point was marginal hospital savings per case of VAP prevented (savings from using silver-coated endotracheal tubes minus… 
Silver tube coatings in pneumonia prevention.
TLDR
More research is needed to assess whether the benefits of silver-coated endotracheal tubes, coupled with additional VAP prevention strategies, outweigh the costs incurred, and if this should not be used as an isolated intervention.
Silver-coated endotracheal tubes for prevention of ventilator-associated pneumonia in critically ill patients.
TLDR
Silver-coated ETTs were associated with delayed time to VAP occurrence and there was a high risk of detection bias owing to lack of blinding of outcomes assessors, but all other domains were assessed to be at low risk of bias.
Ventilator-Associated Pneumonia and the Effectiveness of Endotracheal Tubes Coated with Silver Sulfadiazine
TLDR
A systematic review was conducted to evaluate the effectiveness of silver-coated ETTs for patients that develop VAP and found either a reduction or elimination of bacteria within the ETT, breathing circuit, or lungs of the study subjects.
Ventilator-associated pneumonia as a model for approaching cost-effectiveness and infection prevention in the ICU
TLDR
Understanding the incremental cost-effectiveness of VAP bundles can help prioritize efforts to minimize the associated morbidity, particularly as it relates to such important downstream outcomes of V AP prevention as the use of antibiotics and hospital length of stay.
New endotracheal tubes designed to prevent ventilator-associated pneumonia: do they make a difference?
TLDR
It is critical that future studies of ETTs designed to prevent VAP be adequately powered to demonstrate efficacy on important patient outcomes and safety, in addition to cost-effectiveness.
New issues and controversies in the prevention of ventilator-associated pneumonia.
TLDR
A review of the literature suggests that the use of an endotracheal tube with an ultrathin and tapered-shape cuff membrane and coated in antimicrobial agents may reduce the risk of VAP.
Technologic advances in endotracheal tubes for prevention of ventilator-associated pneumonia.
TLDR
The objective was to review the literature related to recent advances in ETT technologies regarding their impact on the control of microaspiration and biofilm formation in patients on MV, and the subsequent impact on VAP.
Tracheal Tube Design and Ventilator-Associated Pneumonia
TLDR
There is moderate evidence for the use of SSD and strong evidence against the useof tapered-cuff tracheal tubes in critically ill patients for VAP prevention, and more data on the safety and cost-effectiveness of these measures are needed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial.
TLDR
Patients receiving a silver-coated endotracheal tube had a statistically significant reduction in the incidence of VAP and delayed time to VAP occurrence compared with those receiving a similar, uncoated tube.
Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia : potential economic implications.
TLDR
CSS represents a strategy for the prevention of VAP that may result in savings and is demonstrated to be only moderately sensitive to the calculated cost of V AP.
Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units
TLDR
This study provides strong evidence that prevention of VAP by means of oropharyngeal decontamination is cost-effective and simultaneously saves costs.
Clinical and economic consequences of ventilator-associated pneumonia: A systematic review
TLDR
Ventilator-associated pneumonia occurs in a considerable proportion of patients undergoing mechanical ventilation and is associated with substantial morbidity, a two-fold mortality rate, and excess cost, and strategies that effectively prevent VAP are urgently needed.
Impact of a Program of Intensive Surveillance and Interventions Targeting Ventilated Patients in the Reduction of Ventilator-Associated Pneumonia and Its Cost-Effectiveness
TLDR
Intensive surveillance and interventions targeted at ventilated patients resulted in reduction of VAP and appeared to be cost-effective.
Epidemiology and outcomes of ventilator-associated pneumonia in a large US database.
TLDR
It is demonstrated that VAP is a common nosocomial infection that is associated with poor clinical and economic outcomes and strategies to prevent the occurrence of VAP may not reduce mortality, but they may yield other important benefits to patients, their families, and hospital systems.
Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center*
TLDR
Patients with ventilator-associated pneumonia had significantly longer ICU and hospital LOS, with higher crude hospital cost and mortality rate compared with uninfected patients, and hospital costs were higher than average.
Impact of Ventilator-Associated Pneumonia on Resource Utilization and Patient Outcome
TLDR
Ventilator-associated pneumonia negatively affects patient outcome and represents a significant burden on intensive care unit and hospital resources.
Preventing ventilator-associated pneumonia in adults: sowing seeds of change.
TLDR
Prevention and implementation of cost-effective strategies to reduce risk and improve patient outcomes should be prioritized and a multidisciplinary prevention team led by a "champion" is recommended.
Prevention of ventilator-associated pneumonia
  • M. Klompas
  • Medicine
    Expert review of anti-infective therapy
  • 2010
Ventilator-associated pneumonia (VAP) is an important source of morbidity and mortality in critically ill patients. Many interventions are touted to prevent VAP but studies supporting these
...
1
2
3
4
...